650 completed. 650 Phase 2, 121 Phase 1, 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 650 | Completed 650 |
| Phase 1 | 121 | Completed 121 |
| Phase 3 | 16 | Completed 16 |
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer Letrozole, Letrozole and atorvastatin, Fulvestrant - Breast Cancer | Phase 2 | Completed | Lund University Hospital | 126 | 2025-01-02 | 2025-09-10 |
| Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin, Tegodor - Pancreatic Neoplasms, Neoplasm Metastasis | Phase 2 | Completed | Ruijin Hospital | 40 | 2024-08-23 | 2026-03-24 |
| Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer | Phase 2 | Completed | Pedro Barata, MD, MSc | 13 | 2024-05-16 | 2025-05-29 |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Trishula Therapeutics, Inc. | 194 | 2024-03-25 | 2026-05-13 |
| Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 Inhibitors - Metastatic Malignant Solid Neoplasm, Radiotherapy | Phase 2 | Completed | Chuangzhen Chen | 24 | 2023-12-26 | 2026-07-30 |
| Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer Counseling, Psilocybin, Questionnaire Administration - Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | University of Washington | 55 | 2023-06-27 | 2025-11-05 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy Ipilimumab Injection, Atezolizumab Injection, Bevacizumab - HCC - Hepatocellular Carcinoma, Metastatic Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 229 | 2023-03-09 | 2026-03-09 |
| Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer Nab-paclitaxel, Gemcitabine, VCN-01 - Pancreatic Adenocarcinoma, Metastatic | Phase 2 | Completed | Theriva Biologics SL | 112 | 2023-01-10 | 2026-10-30 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071) - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Completed | BioAtla, Inc. | 42 | 2022-12-13 | 2025-09-26 |
| A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer IOA-289 - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | iOnctura | 16 | 2022-10-10 | 2026-03-30 |
| Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Atezolizumab, 6-mercaptopurine, 6-thioguanine - Solid Tumor, Adult, Metastatic Cancer | Phase 1 / Phase 2 | Completed | Kristoffer Rohrberg | 18 | 2022-09-01 | 2026-01-14 |
| Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases Best Practice, Neuropsychological Assessment, Quality-of-Life Assessment - Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 110 | 2022-08-30 | 2026-10-21 |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients avutometinib (VS-6766) and adagrasib - Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | Completed | Verastem, Inc. | 12 | 2022-08-01 | 2026-07-02 |
| Afatinib in Advanced NRG1-Rearranged Malignancies Afatinib 40 MG - Metastatic and Locally Advanced NRG1-rearranged Malignancies | Phase 2 | Completed | German Cancer Research Center | 3 | 2022-07-31 | 2024-04-05 |
| Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Pembrolizumab 25 MG/1 ML Intravenous Solution - Metastatic Uveal Melanoma | Phase 2 | Completed | Institut Curie | 51 | 2022-07-07 | 2026-07-28 |
| Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer Nivolumab, Ipilimumab - Urothelial Cancer | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 25 | 2022-07-06 | 2026-04-24 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
| Targeting ATR in Soft-tissue Sarcomas Association of berzosertib with gemcitabine, Gemcitabine - Leiomyosarcoma, Adult | Phase 2 | Completed | Institut Bergonié | 58 | 2022-02-09 | 2026-05-05 |
Showing 20 of 650. Sign in to see all of them.
Neoplasms (107) · Breast Neoplasms (103) · Colorectal Neoplasms (89) · Melanoma (52) · Prostatic Neoplasms (49) · Carcinoma, Non-Small-Cell Lung (45) · Colonic Neoplasms (42) · Recurrence (42) · Lung Neoplasms (35) · Pancreatic Neoplasms (34) · Rectal Neoplasms (34) · Carcinoma, Renal Cell (33) · Brain Neoplasms (28) · Sarcoma (25)
Pathological Conditions, Signs and Symptoms (650) · Neoplastic Processes (648) · Pathologic Processes (648) · Neoplasms (543) · Neoplasms by Site (503) · Neoplasms by Histologic Type (220) · Digestive System Diseases (181) · Digestive System Neoplasms (179) · Skin and Connective Tissue Diseases (153) · Skin Diseases (152) · Neoplasms, Glandular and Epithelial (141) · Gastrointestinal Diseases (128) · Urogenital Diseases (125) · Urogenital Neoplasms (122) · Gastrointestinal Neoplasms (119)
Gemcitabine (50) · Oxaliplatin (42) · Capecitabine (39) · Fluorouracil (37) · Paclitaxel (36) · Bevacizumab (32) · Docetaxel (31) · Carboplatin (29) · Leucovorin (29) · Cisplatin (28) · Cetuximab (27) · Irinotecan (24) · Nivolumab (21) · Trastuzumab (20) · pembrolizumab (17)
M.D. Anderson Cancer Center (25) · Amgen (18) · National Cancer Institute (NCI) (15) · Dana-Farber Cancer Institute (12) · Eli Lilly and Company (12) · Memorial Sloan Kettering Cancer Center (12) · H. Lee Moffitt Cancer Center and Research Institute (10) · UNICANCER (9) · University Health Network, Toronto (9) · Alliance for Clinical Trials in Oncology (8) · Novartis Pharmaceuticals (8) · AstraZeneca (7) · Massachusetts General Hospital (7) · Sanofi (7) · Bayer (6)
United States (386) · France (106) · Spain (82) · Italy (65) · United Kingdom (61) · Germany (60) · Canada (59) · Belgium (58) · South Korea (37) · Australia (36) · Netherlands (31) · Poland (31) · Russia (27) · Hungary (24) · China (23)
Darell D. Bigner, MD, PhD (3) · John D. Hainsworth, MD (3) · Alessandro M Gianni, MD (2) · Andrea Necchi, MD (2) · Anli Tong (2) · Antonio Lambiase, MD (2) · Christopher Logothetis, MD (2)
PMID 37146227, PMID 33138866, PMID 34213592, PMID 42186347, PMID 10493478, PMID 14673042, PMID 15908664, PMID 16009952, PMID 16230673, PMID 16314647, PMID 16622264, PMID 16859580, PMID 17050875, PMID 17418968, PMID 17470864, PMID 17554116, PMID 17671985, PMID 17704420, PMID 17785764, PMID 17876014, PMID 17987262, PMID 18008108, PMID 18077217, PMID 18316791, PMID 18316792, PMID 18334033, PMID 19114683, PMID 19403935, PMID 19692142, PMID 19965914, PMID 20209610, PMID 20350333, PMID 20362507, PMID 20430469, PMID 20439193, PMID 20576718, PMID 20593550, PMID 20595147, PMID 20652398, PMID 20690802, PMID 21071270, PMID 21217058, PMID 21228335, PMID 21234281, PMID 21290244, PMID 21597387, PMID 21730275, PMID 21784628, PMID 21917625, PMID 21941281
2008 (9), 2014 (7), 2016 (7), 2009 (6), 2018 (6), 2019 (6), 2017 (5), 2005 (4), U10CA032102 (4), P30CA016672 (3), 2004 (2), P30CA033572 (2), P30CA043703 (2), U10CA021115 (2), U10CA180888 (2)